Metabolic Regulation of Erythrocyte Development and Disorders

Overview

Journal Exp Hematol

Specialty Hematology

Date 2024 Jan 18

PMID 38237718

Authors

Junhua Lyu

Min Ni

Mitchell J Weiss

Jian Xu

Affiliations

Soon will be listed here.

Abstract

The formation of new red blood cells (RBC) (erythropoiesis) has served as a paradigm for understanding cellular differentiation and developmental control of gene expression. The metabolic regulation of this complex, coordinated process remains poorly understood. Each step of erythropoiesis, including lineage specification of hematopoietic stem cells, proliferation, differentiation, and terminal maturation into highly specialized oxygen-carrying cells, has unique metabolic requirements. Developing erythrocytes in mammals are also characterized by unique metabolic events such as loss of mitochondria with switch to glycolysis, ejection of nucleus and organelles, high-level heme and hemoglobin synthesis, and antioxidant requirement to protect hemoglobin molecules. Genetic defects in metabolic enzymes, including pyruvate kinase and glucose-6-phosphate dehydrogenase, cause common erythrocyte disorders, whereas other inherited disorders such as sickle cell disease and β-thalassemia display metabolic abnormalities associated with disease pathophysiology. Here we describe recent discoveries on the metabolic control of RBC formation and function, highlight emerging concepts in understanding the erythroid metabolome, and discuss potential therapeutic benefits of targeting metabolism for RBC disorders.

Citing Articles

Are Mitochondria a Potential Target for Treating β-Thalassemia?.

Pierro E, Stefano V, Migone De Amicis M, Graziadei G J Clin Med. 2025; 14(4).

PMID: 40004626 PMC: 11856739. DOI: 10.3390/jcm14041095.

A glutamine metabolic switch supports erythropoiesis.

Lyu J, Gu Z, Zhang Y, Vu H, Lechauve C, Cai F Science. 2024; 386(6723):eadh9215.

PMID: 39541460 PMC: 11749836. DOI: 10.1126/science.adh9215.

Mitochondrial regulation of erythropoiesis in homeostasis and disease.

Menon V, Slavinsky M, Hermine O, Ghaffari S Br J Haematol. 2024; 205(2):429-439.

PMID: 38946206 PMC: 11619715. DOI: 10.1111/bjh.19600.

References

Wingert R, Galloway J, Barut B, Foott H, Fraenkel P, Axe J . Deficiency of glutaredoxin 5 reveals Fe-S clusters are required for vertebrate haem synthesis. Nature. 2005; 436(7053):1035-39. DOI: 10.1038/nature03887. View

Platt O, Orkin S, Dover G, Beardsley G, Miller B, Nathan D . Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest. 1984; 74(2):652-6. PMC: 370519. DOI: 10.1172/JCI111464. View

Mohandas N, Gallagher P . Red cell membrane: past, present, and future. Blood. 2008; 112(10):3939-48. PMC: 2582001. DOI: 10.1182/blood-2008-07-161166. View

Ruan B, Paulson R . Metabolic regulation of stress erythropoiesis, outstanding questions, and possible paradigms. Front Physiol. 2023; 13:1063294. PMC: 9849390. DOI: 10.3389/fphys.2022.1063294. View

Schippel N, Sharma S . Dynamics of human hematopoietic stem and progenitor cell differentiation to the erythroid lineage. Exp Hematol. 2023; 123:1-17. PMC: 10330572. DOI: 10.1016/j.exphem.2023.05.001. View

Kuo K, Layton D, Lal A, Al-Samkari H, Bhatia J, Kosinski P . Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent α-thalassaemia or β-thalassaemia: an open-label, multicentre, phase 2 study. Lancet. 2022; 400(10351):493-501. DOI: 10.1016/S0140-6736(22)01337-X. View

Safo M, Kato G . Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin. Hematol Oncol Clin North Am. 2014; 28(2):217-31. PMC: 4195245. DOI: 10.1016/j.hoc.2013.11.001. View

Musharraf S, Iqbal A, Ansari S, Parveen S, Khan I, Siddiqui A . β-Thalassemia Patients Revealed a Significant Change of Untargeted Metabolites in Comparison to Healthy Individuals. Sci Rep. 2017; 7:42249. PMC: 5304209. DOI: 10.1038/srep42249. View

Higgs D, Engel J, Stamatoyannopoulos G . Thalassaemia. Lancet. 2011; 379(9813):373-83. DOI: 10.1016/S0140-6736(11)60283-3. View

10.

Intlekofer A, Finley L . Metabolic signatures of cancer cells and stem cells. Nat Metab. 2019; 1(2):177-188. PMC: 6594714. DOI: 10.1038/s42255-019-0032-0. View

11.

Filippi M, Ghaffari S . Mitochondria in the maintenance of hematopoietic stem cells: new perspectives and opportunities. Blood. 2019; 133(18):1943-1952. PMC: 6497515. DOI: 10.1182/blood-2018-10-808873. View

12.

Lechauve C, Keith J, Khandros E, Fowler S, Mayberry K, Freiwan A . The autophagy-activating kinase ULK1 mediates clearance of free α-globin in β-thalassemia. Sci Transl Med. 2019; 11(506). PMC: 7441525. DOI: 10.1126/scitranslmed.aav4881. View

13.

Glenthoj A, van Beers E, Al-Samkari H, Viprakasit V, Kuo K, Galacteros F . Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial. Lancet Haematol. 2022; 9(10):e724-e732. DOI: 10.1016/S2352-3026(22)00214-9. View

14.

Burch J, Marcero J, Maschek J, Cox J, Jackson L, Medlock A . Glutamine via α-ketoglutarate dehydrogenase provides succinyl-CoA for heme synthesis during erythropoiesis. Blood. 2018; 132(10):987-998. PMC: 6128084. DOI: 10.1182/blood-2018-01-829036. View

15.

Sun K, DAlessandro A, Ahmed M, Zhang Y, Song A, Ko T . Structural and Functional Insight of Sphingosine 1-Phosphate-Mediated Pathogenic Metabolic Reprogramming in Sickle Cell Disease. Sci Rep. 2017; 7(1):15281. PMC: 5681684. DOI: 10.1038/s41598-017-13667-8. View

16.

Moriconi C, Dzieciatkowska M, Roy M, DAlessandro A, Roingeard P, Lee J . Retention of functional mitochondria in mature red blood cells from patients with sickle cell disease. Br J Haematol. 2022; 198(3):574-586. PMC: 9329257. DOI: 10.1111/bjh.18287. View

17.

Takubo K, Goda N, Yamada W, Iriuchishima H, Ikeda E, Kubota Y . Regulation of the HIF-1alpha level is essential for hematopoietic stem cells. Cell Stem Cell. 2010; 7(3):391-402. DOI: 10.1016/j.stem.2010.06.020. View

18.

Rossmann M, Hoi K, Chan V, Abraham B, Yang S, Mullahoo J . Cell-specific transcriptional control of mitochondrial metabolism by TIF1γ drives erythropoiesis. Science. 2021; 372(6543):716-721. PMC: 8177078. DOI: 10.1126/science.aaz2740. View

19.

Caielli S, Cardenas J, de Jesus A, Baisch J, Walters L, Blanck J . Erythroid mitochondrial retention triggers myeloid-dependent type I interferon in human SLE. Cell. 2021; 184(17):4464-4479.e19. PMC: 8380737. DOI: 10.1016/j.cell.2021.07.021. View

20.

Xu J, Conrey A, Frey I, Gwaabe E, Menapace L, Tumburu L . A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease. Blood. 2022; 140(19):2053-2062. PMC: 9837441. DOI: 10.1182/blood.2022015403. View